The overall 5-year relative survival rate for stomach cancer is 39.8%, based on the most recent data from the National Cancer Institute’s SEER program (2016–2022). That number represents all stages combined, and the reality is that stage at diagnosis dramatically changes the picture, ranging from 75% for cancers caught early to 7% for those that have already spread to distant organs.
Survival Rates by Stage
Stage is the single biggest factor in stomach cancer survival. The National Cancer Institute breaks it into three categories based on how far the cancer has spread at the time of diagnosis:
- Localized (cancer is only in the stomach): 75% five-year relative survival
- Regional (cancer has spread to nearby lymph nodes or organs): 35% five-year relative survival
- Distant/metastatic (cancer has spread to a distant part of the body): 7% five-year relative survival
The gap between localized and distant disease is enormous, which is why early detection matters so much. Unfortunately, stomach cancer rarely causes obvious symptoms in its early stages. Vague complaints like bloating, mild nausea, or feeling full quickly overlap with dozens of common, harmless conditions. By the time more alarming symptoms appear, such as unintentional weight loss, persistent vomiting, or blood in the stool, the cancer has often progressed beyond the stomach.
What “5-Year Relative Survival” Actually Means
A 5-year relative survival rate compares people with stomach cancer to the general population. If the rate is 75%, that means people with that stage of stomach cancer are 75% as likely to be alive five years after diagnosis as people without the disease. It does not mean you have a 75% chance of being cured, nor does it mean you will only live five years. Many people live well beyond that mark. These statistics also reflect outcomes from patients diagnosed several years ago, so they don’t fully capture improvements in treatment that have emerged recently.
Long-Term Survival Beyond Five Years
For patients who reach the five-year milestone, the outlook continues to be cautiously encouraging. One large study tracking gastric cancer patients over decades found a 10-year survival rate of 52.4% and a 20-year survival rate of 40.4%. That means a significant share of people who survive the first five years remain alive much longer. The study also found that patients who received additional therapy after surgery had meaningfully better 10-year survival: 62.3% compared to 50.5% for those who did not.
Late recurrence remains a real concern even after successful treatment. Stomach cancer can return years after initial surgery, which is why follow-up monitoring typically continues for a long time.
How Surgery Affects Outcomes
For patients whose tumors can be completely removed with clean surgical margins (meaning no cancer cells are found at the edges of the tissue taken out), the five-year survival rate is substantially higher than the overall average. A study of over 6,800 patients who had complete surgical removal showed five-year survival rates near 80% to 85%, depending on tumor location. This underscores that when stomach cancer is operable and the surgeon can remove all visible disease, the prognosis improves considerably.
Not every patient is a candidate for this kind of surgery. If the cancer has grown into critical structures or spread widely, complete removal may not be possible. In those cases, treatment focuses on controlling the disease and maintaining quality of life.
How Newer Treatments Are Shifting the Numbers
Immunotherapy has become an important part of stomach cancer treatment, particularly for advanced disease that can’t be cured with surgery alone. These drugs work by helping the immune system recognize and attack cancer cells. The benefits depend on the biological characteristics of each patient’s tumor.
For patients whose tumors produce high levels of a protein that cancer cells use to hide from the immune system, adding immunotherapy to standard chemotherapy has shown meaningful gains. In one major trial, this combination extended median overall survival from about 11 months to over 14 months and reduced the risk of disease progression or death by 32%. Another trial showed a similar benefit, extending survival from 12.6 to 15.6 months with a 25% reduction in the risk of death.
For patients with lower levels of that protein, the benefit of immunotherapy is less clear. In one study, immunotherapy alone performed about the same as chemotherapy for those patients. This is why oncologists now routinely test tumors to determine which treatments are most likely to help.
HER2 Status and Targeted Therapy
About 10% to 20% of stomach cancers overproduce a protein called HER2, which fuels tumor growth. These patients can receive a targeted drug that blocks HER2 in addition to chemotherapy. In the landmark trial that established this approach, patients with strongly HER2-positive tumors who received the targeted combination lived a median of 16 months, compared to 11.8 months with chemotherapy alone. That translates to a 32% reduction in the risk of death.
HER2 testing is now standard practice for anyone diagnosed with advanced stomach cancer, because it opens the door to a treatment that meaningfully improves outcomes for this specific subset of patients.
Does Age Change the Prognosis?
Stomach cancer is sometimes diagnosed in younger adults, raising the question of whether age itself changes survival odds. Research comparing patients under 40, those between 41 and 65, and those 66 and older found no significant difference in overall survival across the age groups. The median overall survival among all patients in that study was 16 months. Younger patients tend to be diagnosed at more advanced stages (possibly because neither they nor their doctors suspect stomach cancer at a young age), which offsets any advantage their general fitness might provide.
Factors That Influence Your Individual Outlook
Population-level survival statistics are a starting point, but several factors shape any individual’s prognosis beyond stage alone:
- Tumor location: Cancers at the junction where the esophagus meets the stomach behave somewhat differently from those in the lower stomach and may have slightly different outcomes after surgery.
- Tumor biology: HER2 status, the level of immune-related protein expression, and how abnormal the cells look under a microscope all influence how the cancer responds to treatment.
- Surgical completeness: Whether the surgeon can remove all visible cancer with clean margins is one of the strongest predictors of long-term survival.
- Response to treatment: Some tumors shrink dramatically with chemotherapy or immunotherapy, and patients who respond well tend to live longer regardless of their initial stage.
- Overall health: Patients in better general health can tolerate more aggressive treatment, which can improve outcomes.
The 39.8% overall five-year survival rate for stomach cancer reflects all patients across all stages and circumstances. Your own situation may look very different depending on when the cancer was found, what type it is, and how it responds to the treatment options available today.